STRATEC SE

Earnings Release • Jul 25, 2007

News Details

Ad-hoc | 25 July 2007 07:41

STRATEC achieves sales and earnings growth in first half of FY 2007

STRATEC Biomedical Systems AG / Half Year Results/Preliminary Results

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

STRATEC achieves sales and earnings growth in first half of FY 2007

Birkenfeld, July 25, 2007

The Board of Management of STRATEC Biomedical Systems AG, which is listed
in the Prime Standard, hereby announces the preliminary unaudited
consolidated figures of the consolidated STRATEC Group for the first half
of the 2007 financial year as of June 30, 2007 pursuant to IFRS
(International Financial Reporting Standards) and in accordance with
Section 15 of the German Securities Trading Act (WpHG).

Key Figures (EUR 000s) 01.01.- 06.30.2007 01.01.- 06.30.2006 Change
Sales 34,098 32,672 + 4.4%
Gross performance 34,625 32,501 + 6.5%
EBITDA 6,993 5,582 + 25.3%
EBIT 5,897 4,901 + 20.3%
EBT 5,907 4,832 + 22.2%
Consolidated net income 4,185 3,548 + 18.0%
Earnings per share (EUR) 0.37 0.32 + 15.6%

The consolidated STRATEC Group had a total workforce of 256, including
personnel provided by a temporary employment agency, as of June 30, 2007
(previous year: 210).

---

Information and Explaination of the Issuer to this News:

Due to the conversion of the working processes involved in the compilation
of our interim reports in English and German, the publication of the
interim report for the first half of the 2007 financial year will be
postponed by several days. The extensive interim report will be available
for downloading from our internet site from around 3.00 p.m. on August 17,
2007.

The extensive 'Interim Report as of September 30, 2007' will be available
for downloading from our internet site from around 3.00 p.m. on November
15, 2007.

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories, blood banks
and research institutes around the world. The company develops its products
on the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange and on other exchanges.

The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and its subsidiaries STRATEC Biomedical Inc., STRATEC
NewGen GmbH, Robion AG and Sanguin International Ltd., as well as Sanguin
International Inc., a subsidiary of Sanguin International Ltd.

Further information can be obtained from:

STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestrasse 37, 75217 Birkenfeld
Germany
Tel: +49 (0)7082 7916 190
Fax: +49 (0)7082 7916 999
E-mail: ir@stratec-biomedical.de
DGAP 25.07.2007

---

Language: English
Issuer: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Indices:
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr
in Stuttgart, München, Düsseldorf

End of News DGAP News-Service

---